DE602006002982D1 - Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit - Google Patents

Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit

Info

Publication number
DE602006002982D1
DE602006002982D1 DE602006002982T DE602006002982T DE602006002982D1 DE 602006002982 D1 DE602006002982 D1 DE 602006002982D1 DE 602006002982 T DE602006002982 T DE 602006002982T DE 602006002982 T DE602006002982 T DE 602006002982T DE 602006002982 D1 DE602006002982 D1 DE 602006002982D1
Authority
DE
Germany
Prior art keywords
dihydrotetrabenazine
cis
symptoms
treatment
huntington disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006002982T
Other languages
German (de)
English (en)
Inventor
Robert Tridgett
T Filloux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Laboratories International Bermuda SRL
Original Assignee
Cambridge Laboratories Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories Ireland Ltd filed Critical Cambridge Laboratories Ireland Ltd
Publication of DE602006002982D1 publication Critical patent/DE602006002982D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602006002982T 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit Active DE602006002982D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds
PCT/GB2006/002593 WO2007007105A1 (en) 2005-07-14 2006-07-13 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease

Publications (1)

Publication Number Publication Date
DE602006002982D1 true DE602006002982D1 (de) 2008-11-13

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006002982T Active DE602006002982D1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit

Country Status (23)

Country Link
US (1) US20080319000A1 (https=)
EP (2) EP1885363B1 (https=)
JP (1) JP2009501202A (https=)
KR (1) KR20080030666A (https=)
CN (1) CN101282726A (https=)
AT (2) ATE522215T1 (https=)
AU (1) AU2006268098B2 (https=)
CA (1) CA2615077A1 (https=)
CY (1) CY1108653T1 (https=)
DE (1) DE602006002982D1 (https=)
DK (1) DK1885363T3 (https=)
ES (1) ES2314931T3 (https=)
GB (1) GB0514501D0 (https=)
HR (1) HRP20080677T3 (https=)
ME (1) ME01629B (https=)
NZ (1) NZ565522A (https=)
PL (1) PL1885363T3 (https=)
PT (1) PT1885363E (https=)
RS (1) RS50626B (https=)
RU (1) RU2409365C2 (https=)
SI (1) SI1885363T1 (https=)
WO (1) WO2007007105A1 (https=)
ZA (1) ZA200800905B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
AU2018241940B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
AU2020315331A1 (en) * 2019-07-16 2022-02-03 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132147A (en) * 1964-05-05
US3159638A (en) * 1964-12-01 Xcha-chj
US3053845A (en) * 1962-09-11 Benzofykedocolines
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3009918A (en) * 1961-11-21 Chz ch
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3123609A (en) * 1964-03-03 Benzo
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (https=) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
MXPA02010222A (es) * 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma

Also Published As

Publication number Publication date
NZ565522A (en) 2010-04-30
RS50626B (sr) 2010-06-30
PT1885363E (pt) 2009-01-08
DK1885363T3 (da) 2008-12-08
EP2027861B1 (en) 2011-08-31
EP2027861A1 (en) 2009-02-25
CA2615077A1 (en) 2007-01-18
RU2008105590A (ru) 2009-08-20
JP2009501202A (ja) 2009-01-15
CY1108653T1 (el) 2014-04-09
ATE409481T1 (de) 2008-10-15
US20080319000A1 (en) 2008-12-25
ME01629B (me) 2010-06-30
CN101282726A (zh) 2008-10-08
ZA200800905B (en) 2010-04-28
AU2006268098A1 (en) 2007-01-18
SI1885363T1 (sl) 2009-02-28
AU2006268098B2 (en) 2011-02-17
ES2314931T3 (es) 2009-03-16
HK1111085A1 (en) 2008-08-01
WO2007007105A1 (en) 2007-01-18
KR20080030666A (ko) 2008-04-04
ATE522215T1 (de) 2011-09-15
PL1885363T3 (pl) 2009-05-29
HRP20080677T3 (hr) 2009-02-28
RU2409365C2 (ru) 2011-01-20
GB0514501D0 (en) 2005-08-24
EP1885363B1 (en) 2008-10-01
EP1885363A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
DE602006002982D1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
ZA200703110B (en) Compounds, compositions and methods of inhibiting α-synuclein toxicity
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602004020061D1 (de) Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
ATE521608T1 (de) Glucokinaseaktivatoren
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
PT1601352E (pt) Utilização combinada de um fibrato e de orlistat para o tratamento da obesidade
DE60302495D1 (de) Landwirtschaftliche Maschine zur Behandlung von Erntegut
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) , BB